Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Autor: Mayer, Kenneth H1 (AUTHOR), Molina, Jean-Michel2 (AUTHOR), Thompson, Melanie A3 (AUTHOR), Anderson, Peter L4 (AUTHOR), Mounzer, Karam C5 (AUTHOR), De Wet, Joss J6 (AUTHOR), DeJesus, Edwin7 (AUTHOR), Jessen, Heiko8 (AUTHOR), Grant, Robert M9 (AUTHOR), Ruane, Peter J10 (AUTHOR), Wong, Pamela11 (AUTHOR), Ebrahimi, Ramin11 (AUTHOR), Zhong, Lijie11 (AUTHOR), Mathias, Anita12 (AUTHOR), Callebaut, Christian13 (AUTHOR), Collins, Sean E14 (AUTHOR), Das, Moupali14 (AUTHOR), McCallister, Scott14 (AUTHOR), Brainard, Diana M14 (AUTHOR), Brinson, Cynthia15 (AUTHOR)
Zdroj: Lancet. 7/25/2020, Vol. 396 Issue 10246, p239-254. 16p.
Databáze: Academic Search Ultimate
Externí odkaz: